Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.

Authors:
Njoroge JN; Teerlink JR.

Journal:
Circ Res

Publication Year: 2021

DOI:
10.1161/CIRCRESAHA.121.318186

PMCID:
PMC8126502

PMID:
33983837

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Circ Res

Abbreviation: Circ Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Directional Endothelial Communication by Polarized Extracellular Vesicle Release.
Raju S; Botts SR; Blaser MC and 16 more (2024) - Transparency Score: 4/6
Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR.
Murugesan P; Zhang Y; Huang Y and 6 more (2024) - Transparency Score: 3/6
Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness.
Faleeva M; Ahmad S; Theofilatos K and 7 more (2024) - Transparency Score: 4/6
Cardiac Alternans: From Bedside to Bench and Back.
Qu Z; Weiss JN. (2023) - Transparency Score: 3/6
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease.
Hutcheson JD; Goettsch C. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures Dr Teerlink has received research grants and consulting fees from Abbott Laboratories, Amgen, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cytokinetics, EBR Systems, LivaNova, Medtronic, Merck, Novartis, Servier, Windtree Therapeutics and serves as Treasurer to Heart Failure Society of America. Dr. Njoroge reports no conflicts."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025